Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Sep 5:12:1756284819870960.
doi: 10.1177/1756284819870960. eCollection 2019.

Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections

Chia-Jung Kuo  1 , Chun-Wei Chen  1 , Puo-Hsien Le  1 , Jun-Te Hsu  2 , Cheng-Yu Lin  1 , Hao-Tsai Cheng  1 , Ming-Yao Su  1 , Chun-Jung Lin  1 , Cheng-Tang Chiu  3
Affiliations

Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections

Chia-Jung Kuo et al. Therap Adv Gastroenterol. .

Abstract

Background: Dexlansoprazole has been shown to be efficacious for the treatment of gastroesophageal reflux disease. However, there is a paucity of data about its efficacy for Helicobacter pylori eradication. The aim of this study was to evaluate the efficacy of dexlansoprazole for H. pylori eradication as triple therapy in real-world practice.

Methods: Adult patients with endoscopically proven H. pylori related peptic ulcer diseases or gastritis were recruited for this study. The eradication status was assessed based on the results of the 13C-urea breath test performed 4 weeks after treatment. According to the different treatment regimens, the patients were allocated to group A: Esomeprazole 40 mg b.i.d. + amoxicillin 1 g b.i.d. + clarithromycin 500 mg b.i.d. for 7 days; group B: Esomeprazole 40 mg q.d. + amoxicillin 1 g b.i.d. + clarithromycin 500 mg b.i.d. for 7 days, or group C: Dexlansoprazole 60 mg q.d. + amoxicillin 1 g b.i.d. + clarithromycin 500 mg b.i.d. for 7 days.

Results: A total of 215 patients (49% males) were enrolled in this study, with a mean age of 55 years. The eradication rates in group A, B, and C were 94.7% (71/75), 89.6% (69/77), and 93.7% (59/63) (p = 0.457), respectively. The adverse events were similar between the three groups (p = 0.068).

Conclusions: This study suggests that dexlansoprazole-based triple therapy has an acceptable eradication rate for H. pylori infection.

Keywords: Helicobacter pylori eradication; dexlansoprazole; proton pump inhibitor.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The author(s) received no financial support for the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Schematic flow chart of the study design.
See this image and copyright information in PMC

References

    1. Jonaitis L, Pellicano R, Kupcinskas L. Helicobacter pylori and nonmalignant upper gastrointestinal diseases. Helicobacter 2018; 23(Suppl. 1): e12522. - PubMed
    1. Malfertheiner P, Chan FK, McColl KE. Peptic ulcer disease. Lancet (London, England) 2009; 374: 1449–1461. - PubMed
    1. Malfertheiner P, Megraud F, O’Morain CA, et al.; European Helicobacter and Microbiota Study Group and Consensus Panel. Management of Helicobacter pylori infection—the Maastricht V/Florence consensus report. Gut 2017; 66: 6–30. - PubMed
    1. Yang JC, Lu CW, Lin CJ. Treatment of Helicobacter pylori infection: current status and future concepts. World J Gastroenterol 2014; 20: 5283–5293. - PMC - PubMed
    1. Hassan IJ, Stark RM, Greenman J, et al. Activities of beta-lactams and macrolides against Helicobacter pylori. Antimicrob Agents Chemother 1999; 43: 1387–1392. - PMC - PubMed

LinkOut - more resources